Marinus Pharma (MRNS) to Offer Common Stock

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Marinus. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Marinus intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares offered in the public offering.

Cowen and Cantor Fitzgerald & Co. are acting as lead book-running managers for the offering. SunTrust Robinson Humphrey is acting as a bookrunner for the offering. Oppenheimer & Co. Inc. is acting as lead manager for the offering. H.C. Wainwright & Co. is acting as co-manager for the offering.

Marinus intends to use the net proceeds of the offering to fund the development of its product candidates and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies, products or businesses, and investments.

You May Also Be Interested In

• H.C. Wainwright Assumes Larimar Therapeutics (LRMR) at Buy
• Securitize goes public on NYSE after SPAC merger closes
• Nuvectis Pharma prices $100M public offering at $20 per share